Logo Logo
Help
Contact
Switch Language to German

Wicklein, Rebecca; Wauschkuhn, Josephine; Giglhuber, Katrin; Kümpfel, Tania; Hemmer, Bernhard; Havla, Joachim and Knier, Benjamin (2021): Association of peripapillary hyper-reflective ovoid masslike structures and disease duration in primary progressive multiple sclerosis. In: European Journal of Neurology, Vol. 28, No. 12: pp. 4214-4218

Full text not available from 'Open Access LMU'.

Abstract

Background and purpose Peripapillary hyper-reflective ovoid masslike structures (PHOMS) are a novel finding during retinal optical coherence tomography in patients with multiple sclerosis (MS). To date, there are no data on the occurrence of PHOMS in early MS. The aim of this study was to investigate the frequency of PHOMS in patients with first diagnosed early relapsing-remitting MS (RRMS) and to search for associations of PHOMS with disease patterns in different MS subtypes. Methods This was a cross-sectional analysis in two different cohorts: cohort 1, consisting of early RRMS patients (n = 349);cohort 2, consisting of patients with primary progressive MS (PPMS) (n = 66) and RRMS (n = 65). Results Peripapillary hyper-reflective ovoid masslike structures were detected in 18.3% of patients with early RRMS. The occurrence of PHOMS was not associated with age, disease duration and disability. Investigating clinical patterns and the occurrence of PHOMS (cohort 2), an association of PHOMS with higher Expanded Disability Status Scale measures (PHOMS 4.9, 3.7-6.1;no PHOMS 3.5, 3.0-5.3;p = 0.03) and longer disease durations (PHOMS 6.5 years, 1.9-11.0;no PHOMS 1.0 years, 0.0-4.0, p = 0.0007) was found in patients with PPMS but not RRMS. After p value adjustment, the disease duration appeared to be more relevant (beta = 0.16, p = 0.06). Conclusion Peripapillary hyper-reflective ovoid masslike structures were found in 18% of patients with early MS. The presence of PHOMS might be associated with disease progression only in PPMS but not RRMS, suggesting that PHOMS might be embedded in neurodegenerative processes.

Actions (login required)

View Item View Item